<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739891</url>
  </required_header>
  <id_info>
    <org_study_id>CHOLEPREV2021</org_study_id>
    <nct_id>NCT04739891</nct_id>
  </id_info>
  <brief_title>Acute Cholecystitis With Concomitant Choledocholithiasis: Unicentric Study of Prevalence and Predictive Factors</brief_title>
  <acronym>CHOLEPREV</acronym>
  <official_title>Acute Cholecystitis With Concomitant Choledocholithiasis: Unicentric Study of Prevalence and Predictive Factors for Its Diagnosis and Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Mataró</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Mataró</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of cholelithiasis with choledocolithiasis is extensively known, whereas for&#xD;
      Acute Calculous Cholecystitis (ACC) with choledocolithiasis or common bile duct stones&#xD;
      (CBDS), a common entity, there is a lack of protocols for optimising treatment. The main&#xD;
      hypothesis of our study is: a correct stratification of the concomitant CBDS probability at&#xD;
      ACC diagnosis would optimize its treatment as early targeted treatment could be performed.&#xD;
      One-step management of ACC with CBDS by a specialised hepatobiliary team would represent a&#xD;
      benefit to the patient in terms of morbi-mortality, admission time and number of admissions.&#xD;
      The aim of our study is to identify high / intermediate probability criteria for CBDS&#xD;
      associated when diagnosing CA. This is a retrospective study of patients who were operated on&#xD;
      with an emergent cholecystectomy in our center from 01/2012 to 12/2019.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be obtained from the hospital (Consorci Sanitari del Maresme) clinical database.&#xD;
&#xD;
      The Ethics Committee approval has been obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CBDS risk</measure>
    <time_frame>From diagnostic to surgery</time_frame>
    <description>Probability of CBDS presence at the moment of AC diagnose based on classification on risk modified from Maple et al. 2010: high, intermediate or low</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative cholangiography</measure>
    <time_frame>During the surgery</time_frame>
    <description>Percentage of patients who underwent intraoperative cholangiography (IOC) in each group: %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity</measure>
    <time_frame>From surgery to 1 year</time_frame>
    <description>Adverse events (biliary fistula presence and ERCP (endoscopic retrograde cholangiopancreatography) requirements) identification during the postoperative period: Y/N</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>From discharge to 1 year</time_frame>
    <description>Requirement of readmission after discharge</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Cholecystitis</condition>
  <condition>Choledocholithiasis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients who underwent emergent cholecystectomy for acute calculous&#xD;
        cholecystitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non urgent cholecystectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana Ciscar, Mrs</last_name>
    <phone>0034937417700</phone>
    <phone_ext>1141</phone_ext>
    <email>aciscar@casdm.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marina Vila, Mrs</last_name>
    <phone>0034937417700</phone>
    <phone_ext>1141</phone_ext>
    <email>mvilatu@csdm.cat</email>
  </overall_contact_backup>
  <reference>
    <citation>Pisano M, Allievi N, Gurusamy K, Borzellino G, Cimbanassi S, Boerna D, Coccolini F, Tufo A, Di Martino M, Leung J, Sartelli M, Ceresoli M, Maier RV, Poiasina E, De Angelis N, Magnone S, Fugazzola P, Paolillo C, Coimbra R, Di Saverio S, De Simone B, Weber DG, Sakakushev BE, Lucianetti A, Kirkpatrick AW, Fraga GP, Wani I, Biffl WL, Chiara O, Abu-Zidan F, Moore EE, Leppäniemi A, Kluger Y, Catena F, Ansaloni L. 2020 World Society of Emergency Surgery updated guidelines for the diagnosis and treatment of acute calculus cholecystitis. World J Emerg Surg. 2020 Nov 5;15(1):61. doi: 10.1186/s13017-020-00336-x. Review.</citation>
    <PMID>33153472</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Mataró</investigator_affiliation>
    <investigator_full_name>Ana Ciscar</investigator_full_name>
    <investigator_title>General and digestive surgery specialist</investigator_title>
  </responsible_party>
  <keyword>Acute Cholecystitis</keyword>
  <keyword>Choledocholithiasis</keyword>
  <keyword>Urgent cholecystectomy</keyword>
  <keyword>Risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
    <mesh_term>Cholecystitis, Acute</mesh_term>
    <mesh_term>Choledocholithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

